Trial Profile
AN OPEN-LABEL, RANDOMIZED, THREE-PERIOD, TWO-SEQUENCE CROSSOVER, REPEATED-DOSE, REPLICATE DESIGN STUDY TO DETERMINE THE BIOEQUIVALENCE OF TWO DIFFERENT LURASIDONE FORMULATIONS IN PATIENTS WITH SCHIZOPHRENIA, SCHIZOAFFECTIVE, OR SCHIZOPHRENIFORM DISORDER.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 11 Aug 2023
Price :
$35
*
At a glance
- Drugs Lurasidone (Primary)
- Indications Psychotic disorders; Schizoaffective disorder; Schizophrenia
- Focus Pharmacokinetics
- Sponsors Dainippon Sumitomo Pharma
- 12 Mar 2010 New trial record